IMR Press / FBL / Volume 5 / Issue 4 / DOI: 10.2741/chamoun

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Pathophysiologic role of selectins and their ligands in ischemia reperfusion injury
Show Less
1 Division of Nephrology, Hennepin County Medical Center, University of Minnesota Medical School, Minneapolis, MN 55415, USA
Front. Biosci. (Landmark Ed) 2000, 5(4), 103–109; https://doi.org/10.2741/chamoun
Published: 1 November 2000
Abstract

Research findings are unveiling the potential role of leukocytes and leukocyte adhesion molecules such as selectins in ischemia-reperfusion injury (IRI). "Anti-adhesion" therapy using selectin blocking agents may represent a new approach to treatment of the many diverse clinical disorders in which ischemia-reperfusion occurs, including transplantation, reperfusion after thrombotic events and shock. In this paper we review the pathophysiology of IRI, the different types of selectins and selectin ligands, the clinical implications of selectin blockade in different organs with IRI, and new insights into mechanism of action.

Keywords
Selectin
Selectin ligands
Leukocyte Adhesion molecules
Ischemia-reperfusion
Review
Share
Back to top